Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Minerva Neurosciences Inc

NERV ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.54

▲ +2.71%

Market Cap $216.77M · Vol 29.38K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$216.77M

Micro Cap

Div Yield

N/A

EPS Growth

+73.54%

YoY

RSI (14)

58.18

Momentum

Beta

-0.12

vs Market

52W High

$12.46

63.56% below

52W Low

$1.95

132.82% above

Volume

29.38K

Avg 57.87K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

92.58%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Minerva Neurosciences Inc (NERV) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NERV pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.09%

+6.32%

-4.22%

-29.61%

YTD

+12.94%

+86.07%

-47.82%

-70.60%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-293,423,180.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-434.34% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+73.54%
Outstanding Shares	47.75M

Technical Indicators

50-Day SMA	$4.44
200-Day SMA	$5.02
RSI (14)	58.18
Beta	-0.12
52-Week High	$12.46
52-Week Low	$1.95

Volume Today	29.38K
Avg Daily Volume (30D)	57.87K
Relative Volume	0.51x
Volatility (10D)	114.45
Volatility (30D)	86.70
Free Float	92.58%

Analyst Consensus

BUY

Current Price $4.54

Mean Target $10.33

52W Low$1.95 52W High$12.46

Current

Target

$1.95 $12.46

Current Analyst target

+127.61% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0067S9Z82

ISINUS6033802058

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +0.88% ARGX.BR argenx SE +1.73% ARGX argenx SE +0.52% INSM Insmed Inc +0.11% 2269.HK WuXi Biologics (Cayman) Inc +5.24%

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and ?-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.